It has been well documented that T cells from tumor or tumor draining lymph nodes, after activation in vitro, are effective in cancer immunotherapy and could kill tumor cells more effectively in vivo in combination with IL-2 administration [1, 3, 13, 20, 21]. The gene discussed is IL2; the disease is neoplasm.